Scorpion Therapeutics

This week, we celebrated a special milestone - our company anniversary. It's been four years of hard work and dedication, and we’re proud of our achievements that include: 1. Advancing three compounds into development 2. Building a fully-integrated chemistry discovery engine 3. Growing our Scorpion teams in Boston and South San Francisco 4. Presenting a Trial-In-Progress at SABCS alongside Dr. Alberto Montero about our ongoing Phase 1/2 clinical study of STX-478 Here’s to many years ahead of working to deliver transformative medicines to patients!

It's an exciting day for the future of drug discovery in cancer. Scorpion team members alongside Co-Founder Liron Bar-Peled and scientists at Mass General Brigham authored a new study published in Cell, which looked to uncover which proteins may be druggable across cancer. These findings further attest to our commitment to developing the next generation of targeted cancer therapies and transforming the lives of patients. Read more about the study here: https://lnkd.in/emW-cUDz

This week, we celebrated a special milestone - our company anniversary. It's been four years of hard work and dedication, and we’re proud of our achievements that include: 1. Advancing three compounds into development 2. Building a fully-integrated chemistry discovery engine 3. Growing our Scorpion teams in Boston and South San Francisco 4. Presenting a Trial-In-Progress at SABCS alongside Dr. Alberto Montero about our ongoing Phase 1/2 clinical study of STX-478 Here’s to many years ahead of working to deliver transformative medicines to patients!

This International Women’s Day we are pleased to #inspireinclusion by supporting the important work Women's Lunch Place and Dress for Success Boston are doing to uplift women in our community. Their dedication to empowering women is a powerful force for positive change. #InspireInclusion #internationalwomensday Check out a picture from our recent volunteer event with Women's Lunch Place.

Today, we express our profound gratitude to the women of Scorpion for their commitment to transforming the lives of cancer patients. Your contributions are vital, your talent is immeasurable, and your dedication is inspiring. Scorpion is committed to #InspireInclusion and foster a work environment where all feel a sense of belonging. #InternationalWomensDay

Happy #EmployeeAppreciationDay! Today, we celebrate our team at Scorpion for their hard work and dedication to developing the next generation of cancer therapies. Thank you for all you do for Scorpion and for patients!

We are proud to see STX-478 on this illustrious list and in great company!

I'm super excited to announce that I have joined Scorpion Therapeutics as Chief Medical Officer. Looking forward to working with Adam Friedman, MD, PhD, the leadership team, founders (Keith Flaherty, Gaddy Getz, Liron Bar-Peled), board members (Jeff Albers, Jean-Francois Formela, Otello Stampacchia, Arjun Goyal, M.D., Oleg Nodelman, Saurabh Saha MD PhD and Shelley Chu) and the entire team at Scorpion. I have been impressed with the level of science, robust clinical and research pipeline and the people. I'm looking forward to working with the team to help continue its success! https://lnkd.in/gnQwz_p7

As we kick off 2024, we want to share some exciting news about current and new members of our executive leadership team. Adam Friedman, MD, PhD has been appointed as CEO of Scorpion Therapeutics, a move that underscores his many contributions from the company’s inception and sets us up well for our current trajectory of growth. We’re also pleased to announce that accomplished industry veteran, Jeff Albers, has been named Executive Chair of our Board of Directors. Mark Chao, a leading expert in clinical development, has joined Scorpion as its Chief Medical Offer and Erica Jackson has been appointed as our first Chief Discovery Officer. Please join us in extending a big congratulations to Adam, Jeff, Mark and Erica! Learn more: https://bit.ly/3RKu7LK #PrecisionOncology  

STX-721: EGFR Ex20ins Inhibitor with Potential Best-in-Class Selectivity | https://lnkd.in/dYSeJMXx STX-721 is an oral, covalent, mutant-selective inhibitor of EGFR and HER2 Exon 20 insertion (ex20ins) mutants, a well-validated target that saw its first approval with mobocertinib in 2022. Inhibition of wild-type (WT) EGFR is well-established to cause skin and gut toxicities, and selective inhibition of EGFR ex20ins mutants over WT may also allow greater efficacy to be seen at tolerated doses. On Oct. 10th, Scorpion Therapeutics announced that the first patient had been dosed with STX-721 in a Ph. I/II study for EGFR ex20ins mutant NSCLC (NCT06043817). This article highlights the discovery of STX-721 (presented by Ben Milgram, ACS San Francisco, 2023), an excellent case study in covalent drug discovery with respect to lead generation, warhead stability assessment, selectivity based on protein dynamics, and PK optimization of covalent compounds. Full article: https://lnkd.in/dYSeJMXx